Download PDF
Aktuelle Dermatologie 2025; 51(04): 113-121
DOI: 10.1055/a-2490-6663
Originalarbeit

Klinische Relevanz von Wundverbänden mit TLC-NOSF-Matrix im alltäglichen Management chronischer Wunden – Gepoolte Datenanalyse

Clinical relevance of wound dressings with TLC-NOSF matrix in the day-to-day management of chronic wounds – Pooled data analysis
Joachim Dissemond 
1   Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Essen, Deutschland
,
Matthias Augustin
2   Institut für Versorgungsforschung und bei Pflegeberufen (IVDP), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
,
Holger Lawall
3   Gemeinschaftspraxis Prof. Dr. med. Curt Diehm, Dr. med. Holger Lawall, Ettlingen, Deutschland
,
Arthur Grünerbel
4   Diabeteszentrum, Diabeteszentrum München Süd, München, Deutschland
,
Laetitia Thomassin
5   Global Medical Affairs, URGO Medical, Paris, Frankreich
,
Serge Bohbot
5   Global Medical Affairs, URGO Medical, Paris, Frankreich
,
Elisa Häuser
6   Medical Affairs, URGO Medical, Sulzbach, Deutschland
,
Patricia Wilken
6   Medical Affairs, URGO Medical, Sulzbach, Deutschland
,
Ralf Lobmann
7   Klinik für Endokrinologie, Diabetologie und Geriatrie, Zentrum für Innere Medizin, Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Deutschland (Ringgold ID: RIN14999)
› Author Affiliations
Diese Arbeit wurde durch die Fa. URGO GmbH, Sulzbach, Deutschland durchgeführt und finanziert.
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Zielsetzung

In mehreren klinischen Studien konnte gezeigt werden, dass verschiedene Wundverbände mit TLC-NOSF-Matrix die Heilung chronischer Wunden unterstützen und kosteneffektiv sind. Anhand einer gepoolten Analyse aus 2 Beobachtungsstudien sollte daher jetzt die Bewertung der klinischen Relevanz von polyabsorbierenden TLC-NOSF (Sucrose-Octasulfat)-Wundverbänden im ambulanten Praxisalltag untersucht werden.

Methoden

Gepoolte Datenanalyse von 2 prospektiven, multizentrischen Beobachtungsstudien aus den Jahren 2017–2018 (N=1.140 Patienten) und 2019–2020 (N=961 Patienten) mit Ulcus cruris (UC), diabetischem Fußulkus (DFU), Dekubitus oder anderen chronischen Wunden zur Evaluation zahlreicher Wundparameter.

Ergebnisse

Unter Anwendung polyabsorbierender Wundverbände mit der TLC-NOSF-Matrix wurde eine kontinuierliche Verbesserung des Wundheilungsprozesses festgestellt, unabhängig von Art bzw. Ätiologie der chronischen Wunden. Nach einer maximalen Beobachtungsdauer von 12 Wochen hatte sich der Zustand der Wunden bei 93,1% der Patienten verbessert. Dabei wurde umso häufiger ein Wundverschluss erzielt, je eher mit der Behandlung begonnen worden war. Bei ≤1 Monat alten Wunden variierte dies zwischen 54,3% (Dekubitus), 55,9% (UC), 61,0% (andere Wunden) und 64,2% (DFU).

Schlussfolgerung

Diese Ergebnisse entsprechen den bisher bekannten Erkenntnissen aus klinischen Studien für TLC-NOSF-Wundverbände und vervollständigen die Evidenzlage bezüglich der guten, die Wundheilung fördernden Eigenschaften, Sicherheit und Akzeptanz unabhängig von den Charakteristika der Patienten und den Wundeigenschaften auch im ambulanten Praxisalltag in Deutschland. Dies unterstützt die Empfehlungen aktueller nationaler und internationaler Leitlinien und Publikationen, Wundverbände mit der TLC-NOSF-Matrix bei nicht infizierten chronischen Wunden mit einer geeigneten Standardversorgung so früh wie möglich in der Behandlung chronischer Wunden bis zu deren Abheilung einzusetzen.

Abstract

Objective

Different wound dressings with TLC-NOSF matrix support the healing of chronic wounds and are cost-effective as shown in various clinical studies. In a pooled analysis of two observational studies, the clinical relevance of polyabsorbent TLC-NOSF (sucrose octasulfate) wound dressings in everyday outpatient practice should therefore now be analysed.

Methods

A pooled data analysis of two prospective, multicentre observational studies from the years 2017–2018 (N=1,140 patients) and 2019–2020 (N=961 patients) with legs ulcers (LU), diabetic foot ulcers (DFU), pressure ulcers (PU) or other types of chronic wounds was conducted to evaluate several wound parameters.

Results

Using polyabsorbent wound dressings with TLC-NOSF matrix, a continuous improvement in the wound healing process was observed, regardless of the type resp. aetiology of the chronic wounds. After a maximum observation period of 12 weeks, the condition of the wounds had improved in 93.1% of patients. Complete wound healing was achieved more frequently, the earlier treatment was initiated: For wounds with a duration of ≤1 month this varied between 54.3% (PU), 55.9% (LU), 61.0% (other wounds) and 64.2% (DFU).

Conclusion

These results are consistent with previously known findings from clinical studies with TLC-NOSF wound dressings and complete the evidence base regarding their good healing properties, safety and acceptance regardless of patient characteristics and wound properties in everyday outpatient practice in Germany. This supports the recommendations of current national and international guidelines and publications to use wound dressings with TLC-NOSF-matrix for non-infected chronic wounds with an appropriate standard of care as early as possible in the treatment of chronic wounds until they have healed.

Schlüsselwörter

UrgoStart Plus - TLC-NOSF-Wundverband - chronische Wunden - Wundverschluss

Keywords

UrgoStart Plus - TLC-NOSF wound dressing - chronic wounds - wound closure


Publication History

Article published online:
24 April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376: 2367-2375
    CrossrefPubMedSearch in Google Scholar
  • 2 Guest JF, Fuller GW, Vowden P. Cohort study evaluating the burden of wounds to the UK's National Health Service in 2017/2018: Update from 2012/2013. BMJ open 2020; 10: e045253 e045253
    CrossrefPubMedSearch in Google Scholar
  • 3 Lazaro JL, Izzo V, Meaume S. et al. Elevated levels of matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence. J Wound Care 2016; 25: 277-287
    CrossrefPubMedSearch in Google Scholar
  • 4 Armstrong DG, Tan TW, Boulton AJM. et al. Diabetic foot ulcers: A review. JAMA 2023; 330: 62-75
    CrossrefPubMedSearch in Google Scholar
  • 5 Armstrong DG, Swerdlow MA, Armstrong AA. et al. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res 2020; 13: 16
    CrossrefPubMedSearch in Google Scholar
  • 6 Bui UT, Edwards H, Finlayson K. Identifying risk factors associated with infection in patients with chronic leg ulcers. Int Wound J 2018; 15: 283-290
    CrossrefPubMedSearch in Google Scholar
  • 7 Fino P, Di Taranto G, Pierro A. et al. Depression risk among patients with chronic wounds. Eur Rev Med Pharmacol Sci 2019; 23: 4310-4312
    CrossrefPubMedSearch in Google Scholar
  • 8 Green J, Jester R, McKinley R. et al. The impact of chronic venous leg ulcers: a systematic review. J Wound Care 2014; 23: 601-612
    CrossrefPubMedSearch in Google Scholar
  • 9 Leren L, Johansen E, Eide H. et al. Pain in persons with chronic venous leg ulcers: A systematic review and meta-analysis. Int Wound J 2020; 17: 466-484
    CrossrefPubMedSearch in Google Scholar
  • 10 Reinboldt-Jockenhöfer F, Babadagi Z, Hoppe HD. et al. Association of wound genesis on varying aspects of health-related quality of life in patients with different types of chronic wounds: Results of a cross-sectional multicentre study. Int Wound J 2021; 18: 432-439
    CrossrefPubMedSearch in Google Scholar
  • 11 Dissemond J, Augustin M, Dietlein M. et al. Sucrose octasulfate-evidence in the treatment of chronic wounds. Hautarzt 2020; 71: 791-801
    CrossrefPubMedSearch in Google Scholar
  • 12 Edmonds M, Lázaro-Martínez JL, Alfayate-García JM. et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol 2018; 6: 186-196
    CrossrefPubMedSearch in Google Scholar
  • 13 Meaume S, Truchetet F, Cambazard F. et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen 2012; 20: 500-511
    CrossrefPubMedSearch in Google Scholar
  • 14 Münter KC, Meaume S, Augustin M. et al. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26: S4-S15
    CrossrefPubMedSearch in Google Scholar
  • 15 Schmutz JL, Meaume S, Fays S. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Int Wound J 2008; 5: 172-182
    CrossrefPubMedSearch in Google Scholar
  • 16 Augustin M, Herberger K, Kroeger K. et al. Cost-effectiveness of treating vascular leg ulcers with UrgoStart and UrgoCell Contact. Int Wound J 2016; 13: 82-87
    CrossrefPubMedSearch in Google Scholar
  • 17 Dissemond J, Lützkendorf S, Dietlein M. et al. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care 2020; 29: 350-361
    CrossrefPubMedSearch in Google Scholar
  • 18 Lázaro-Martínez JL, Edmonds M, Rayman G. et al. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care 2019; 28: 358-367
    CrossrefPubMedSearch in Google Scholar
  • 19 Lobmann R, Augustin M, Lawall H. et al. Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers. J Wound Care 2019; 28: 808-816
    CrossrefPubMedSearch in Google Scholar
  • 20 Lobmann R, Grünerbel A, Lawall H. et al. Impact of wound duration on diabetic foot ulcer healing: evaluation of a new sucrose octasulfate wound dressing. J Wound Care 2020; 29: 543-551
    CrossrefPubMedSearch in Google Scholar
  • 21 Maunoury F, Oury A, Fortin S. et al. Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France. PloS One 2021; 16: e0245652
    CrossrefPubMedSearch in Google Scholar
  • 22 Meaume S, Dompmartin A, Lok C. et al. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomised controlled trial. J Wound Care 2017; 26: 368-379
    CrossrefPubMedSearch in Google Scholar
  • 23 National Institute for Health and Care Excellence (NICE). UrgoStart for treating diabetic foot ulcers and leg ulcers. Medical technologies guidance [MTG42]. [published: 31 January 2019, last updated: 4 April 2023] Accessed January 09, 2024 at: https://tinyurl.com/6b2k8czb 2023
    CrossrefPubMedSearch in Google Scholar
  • 24 Sigal ML, Addala A, Maillard H. et al. Evaluation of TLC-NOSF dressing with poly-absorbent fibres in exuding leg ulcers: two multicentric, single-arm, prospective, open-label clinical trials. J Wound Care 2019; 28: 164-175
    CrossrefPubMedSearch in Google Scholar
  • 25 Wen J, Jin X, Al Sayah F. et al. Economic evaluation of sucrose octasulfate dressing for treatment of diabetic foot ulcers in patients with type 2 diabetes. Can J Diabetes 2022; 46: 126-133
    CrossrefPubMedSearch in Google Scholar
  • 26 Augustin M, Keuthage W, Lobmann R. et al. Clinical evaluation of UrgoStart Plus dressings in real-life conditions: results of a prospective multicentre study on 961 patients. J Wound Care 2021; 30: 966-978
    CrossrefPubMedSearch in Google Scholar
  • 27 Augustin M, Baade K, Herberger K. et al. Use of the WoundQoL instrument in routine practice: Feasibility, validity and development of an implementation tool. Wound Med 2014; 5: 4-8
    CrossrefPubMedSearch in Google Scholar
  • 28 Blome C, Baade K, Debus ES. et al. The “Wound-QoL”: a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen 2014; 22: 504-514
    CrossrefPubMedSearch in Google Scholar
  • 29 Binder B, Dissemond J, Hämmerle G. et al. Guideline for the treatment of chronic wounds with polyabsorbent TLC-Sucrose Octasulfate wound dressings. WUNDmanagement 2021; 15: 181-190
    PubMedSearch in Google Scholar
  • 30 Deutsche Gesellschaft für Wundheilung und Wundbehandlung e.V. (DGfW; Hrsg.). Lokaltherapie schwerheilender und/oder chronischer Wunden aufgrund von peripherer arterieller Verschlusskrankheit, Diabetes mellitus oder chronischer venöser Insuffizienz. Version 2.1. Stand: 11.09.2023. AWMF-Register-Nr.: 091/001 Accessed July 08, 2024 at: https://register.awmf.org/de/leitlinien/detail/091-001
    PubMed
  • 31 Schaper NC, van Netten JJ, Apelqvist J. et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev 2024; 40: e3657
    CrossrefPubMedSearch in Google Scholar